Histone deacetylase regulates insulin signaling via two pathways in pancreatic β cells

PLoS ONE

Volumn 12, Issue 9, 2017, Pages

  Kawada, Yukina ^a   Asahara, Shun Ichiro ^b   Sugiura, Yumiko ^a   Sato, Ayaka ^b   Furubayashi, Ayuko ^b   Kawamura, Mao ^b   Bartolome, Alberto ^c   Terashi Suzuki, Emi ^b   Takai, Tomoko ^b   Kanno, Ayumi ^b   Koyanagi Kimura, Maki ^b   Matsuda, Tomokazu ^b   Hashimoto, Naoko ^b   Kido, Yoshiaki ^a,b  

^a KOBE UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CYCLINE; DNA; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; ISOPROTEIN; LYSINE; PROTEIN H3K9; TYROSINE; UNCLASSIFIED DRUG; HISTONE; INSULIN RECEPTOR SUBSTRATE;

ANIMAL CELL; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL NUCLEUS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME REGULATION; EPIGENETIC CONTROL; EPIGENETICS; GENE EXPRESSION; GENE NUMBER; HIGH PASSAGE NUMBER; INSULIN SIGNALING; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PROMOTER REGION; PROTEIN ACETYLATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; UPREGULATION; ACETYLATION; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ACETYLATION; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-SECRETING CELLS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION;

EID: 85029376153     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0184435     Document Type: Article

References (49)

1. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999; 104: 787–794. https://doi.org/10.1172/JCI7231 PMID: 10491414
2. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science. 2005; 307: 380–384. https://doi.org/10.1126/science.1104345 PMID: 15662003
3. Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest. 2006; 116: 1756–1760. https://doi.org/10.1172/JCI29189 PMID: 16823472
4. Giannini C, Weiss R, Cali A, Bonadonna R, Santoro N, Pierpont B, et al. Evidence for early defects in insulin sensitivity and secretion before the onset of glucose dysregulation in obese youths: a longitudinal study. Diabetes. 2012; 61: 606–614. https://doi.org/10.2337/db11-1111 PMID: 22315322
5. Festa A, Williams K, Hanley AJ, Haffner SM. Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes. 2008; 57: 1638–1644. https://doi.org/10.2337/db07-0954 PMID: 18332099
6. Costes S, Langen R, Gurlo T, Matveyenko AV, Butler PC. β-Cell failure in type 2 diabetes: a case of asking too much of too few? Diabetes. 2013; 62: 327–335. https://doi.org/10.2337/db12-1326 PMID: 23349537
7. Weir GC, Bonner-Weir S. Islet β cell mass in diabetes and how it relates to function, birth, and death. Ann N Y Acad Sci. 2013; 1281: 92–105. https://doi.org/10.1111/nyas.12031 PMID: 23363033
8. Ueki K, Okada T, Hu J, Liew CW, Assmann A, Dahlgren GM, et al. Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. Nat Genet. 2006; 38: 583–588. https://doi.org/10.1038/ng1787 PMID: 16642022
9. Okada T, Liew CW, Hu J, Hinault C, Michael MD, Krtzfeldt J, et al. Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. Proc Natl Acad Sci U S A. 2007; 22: 8977–8982.
10. Otani K, Kulkarni RN, Baldwin AC, Krutzfeldt J, Ueki K, Stoffel M, et al. Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in betaIRKO mice. Am J Physiol Endocrinol Metab. 2004; 286: E41–E49. https://doi.org/10.1152/ajpendo.00533.2001 PMID: 14519599
11. Hashimoto N, Kido Y, Uchida T, Asahara S, Shigeyama Y, Matsuda T, et al. Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat Genet. 2006; 38: 589–593. https://doi.org/10.1038/ng1774 PMID: 16642023
12. Shigeyama Y, Kobayashi T, Kido Y, Hashimoto N, Asahara S, Matsuda T, et al. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Mol Cell Biol. 2008; 28: 2971–2979. https://doi.org/10.1128/MCB.01695-07 PMID: 18316403
13. Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C, et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ. 1991; 303: 1019–1022. PMID: 1954451
14. Phipps K, Barker DJ, Hales CN, Fall CH, Osmond C, Clark PM. Fetal growth and impaired glucose tolerance in men and women. Diabetologia. 1993; 36: 225–228. PMID: 8462770
15. Inoue T, Kido Y, Asahara S, Matsuda T, Shibutani Y, Koyanagi M, et al. Effect of intrauterine undernutrition during late gestation on pancreatic beta cell mass. Biomed Res. 2009; 30: 325–330. PMID: 20051640
16. Yoshida Y, Fuchita M, Kimura-Koyanagi M, Kanno A, Matsuda T, Ashahara S, et al. Contribution of insulin signaling to the regulation of pancreatic beta-cell mass during the catch-up growth period in a low birth weight mouse model. Diabetology Int. 2014; 5: 43–52.
17. Park JH, Stoffers DA, Nicholls RD, Simmons RA. Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest. 2008; 118: 2316–2324. https://doi.org/10.1172/JCI33655 PMID: 18464933
18. Asahara S, Shibutani Y, Teruyama K, Inoue HY, Kawada Y, Etoh H, et al. Ras-related C3 botulinum toxin substrate 1 (RAC1) regulates glucose-stimulated insulin secretion via modulation of F-actin. Diabetologia. 2013; 56: 1088–1097. https://doi.org/10.1007/s00125-013-2849-5 PMID: 23412604
19. Kanno A, Asahara S, Masuda K, Matsuda T, Kimura-Koyanagi M, Seino S, et al. Compensatory hyperinsulinemia in high-fat diet-induced obese mice is associated with enhanced insulin translation in islets. Biochem Biophys Res Commun. 2015; 458: 681–686. https://doi.org/10.1016/j.bbrc.2015.02.024 PMID: 25686499
20. Asahara S, Matsuda T, Kido Y, Kasuga M. Increased ribosomal biogenesis induces pancreatic beta cell failure in mice model of type 2 diabetes. Biochem Biophys Res Commun. 2009; 381: 367–371. PMID: 19309774
21. O’Driscoll L, Gammell P, McKiernan E, Ryan E, Jeppesen PB, Rani S, et al. Phenotypic and global gene expression profile changes between low passage and high passage MIN-6 cells. J Endocrinol. 2006; 191: 665–676. https://doi.org/10.1677/joe.1.06894 PMID: 17170223
22. Neelankal John A, Morahan G, Jiang FX. Incomplete re-expression of neuroendocrine progenitor/stem cell markers is a key feature of β-cell dedifferentiation. J Neuroendocrinol. 2017 Jan; 29. https://doi.org/10.1111/jne.12450 PMID: 27891681
23. Jhala US, Canettieri G, Screaton RA, Kulkarni RN, Krajewski S, Reed J, et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev. 2003; 17: 1575–1580. https://doi.org/10.1101/gad.1097103 PMID: 12842910
24. Nakamura A, Togashi Y, Orime K, Sato K, Shirakawa J, Ohsugi M, et al. Control of beta cell function and proliferation in mice stimulated by small-molecule glucokinase activator under various conditions. Diabetologia. 2012; 55: 1745–1754. https://doi.org/10.1007/s00125-012-2521-5 PMID: 22456697
25. Liu Z, Kim W, Chen Z, Shin YK, Carlson OD, Fiori JL, et al. Insulin and glucagon regulate pancreatic α-cell proliferation. PLoS One. 2011; 6: e16096. https://doi.org/10.1371/journal.pone.0016096 PMID: 21283589
26. Li Y, Xu W, McBurney MW, Longo VD. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab. 2008; 8: 38–48. https://doi.org/10.1016/j.cmet.2008.05.004 PMID: 18590691
27. Meng Z, Jia LF, Gan YH. PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition. Oncogene. 2016; 35: 2333–2344. https://doi.org/10.1038/onc.2015.293 PMID: 26279303
28. Miyake K, Ogawa W, Matsumoto M, Nakamura T, Sakaue H, Kasuga M. Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver. J Clin Invest. 2002; 110: 1483–1491. https://doi.org/10.1172/JCI15880 PMID: 12438446
29. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006; 91: 4753–4761. https://doi.org/10.1210/jc.2006-0587 PMID: 16968800
30. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006; 7: 85–96. https://doi.org/10.1038/nrm1837 PMID: 16493415
31. Yamato E, Tashiro F, Miyazaki J. Microarray analysis of novel candidate genes responsible for glucose-stimulated insulin secretion in mouse pancreatic β cell line MIN6. PLoS One. 2013; 8: e61211. https://doi.org/10.1371/journal.pone.0061211 PMID: 23560115
32. Cheng K, Delghingaro-Augusto V, Nolan CJ, Turner N, Hallahan N, Andrikopoulos S, et al. High passage MIN6 cells have impaired insulin secretion with impaired glucose and lipid oxidation. PLoS One. 2012; 7: e40868. https://doi.org/10.1371/journal.pone.0040868 PMID: 22808281
33. Lundh M, Christensen DP, Damgaard Nielsen M, Richardson SJ, Dahllöf MS, Skovgaard T, et al. Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children. Diabetologia. 2012; 55: 2421–2431. https://doi.org/10.1007/s00125-012-2615-0 PMID: 22772764
34. Gluckman PD, Lillycrop KA, Vickers MH, Pleasants AB, Phillips ES, et al. Metabolic plasticity during mammalian development is directionally dependent on early nutritional status. Proc Natl Acad Sci U S A. 2007; 104: 12796–12800. https://doi.org/10.1073/pnas.0705667104 PMID: 17646663
35. Asahara S, Etoh H, Inoue H, Teruyama K, Shibutani Y, Ihara Y, et al. Paternal allelic mutation at the Kcnq1 locus reduces pancreatic β cell mass via epigenetic modification of Cdkn1c. Proc Natl Acad Sci U S A. 2015; 112: 8332–8337. https://doi.org/10.1073/pnas.1422104112 PMID: 26100882
36. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003; 370: 737–749. https://doi.org/10.1042/ BJ20021321 PMID: 12429021
37. Wang J, Gong B, Zhao W, Tang C, Varghese M, Nguyen N, et al. Epigenetic mechanisms linking diabetes and synaptic impairments. Diabetes. 2013; 63: 645–654. https://doi.org/10.2337/db13-1063 PMID: 24154559
38. Funato H, Oda S, Yokofujita J, Igarashi H, Kuroda M. Fasting and high-fat diet alter histone deacetylase expression in the medial hypothalamus. PLoS One. 2011; 6: e18950. https://doi.org/10.1371/journal.pone.0018950 PMID: 21526203
39. Lee HB, Noh H, Seo JY, Yu MR, Ha H. Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy. Kidney Int Suppl. 2007; 106: S61–66.
40. Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, et al. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol. 2009; 297: F729–739. https://doi.org/10.1152/ajprenal.00086.2009 PMID: 19553350
41. Lenoir O, Flosseau K, Ma FX, Blondeau B, Mai A, Bassel-Duby R, et al. Specific control of pancreatic endocrine beta- and delta-cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9. Diabetes. 2011; 60: 2861–2871. https://doi.org/10.2337/db11-0440 PMID: 21953612
42. Daneshpajooh M, Bacos K, Bysani M, Bagge A, Ottosson Laakso E, Vikman P, et al. HDAC7 is overexpressed in human diabetic islets and impairs insulin secretion in rat islets and clonal beta cells. Diabetologia. 2017; 60: 116–125. https://doi.org/10.1007/s00125-016-4113-2 PMID: 27796421
43. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997; 90: 595–606. PMID: 9288740
44. Giandomenico V, Simonsson M, Gronroos E, Ericsson J. Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol Cell Biol. 2003; 23: 2587–2599. https://doi.org/10.1128/MCB.23.7.2587-2599.2003 PMID: 12640139
45. Daitoku H, Hatta M, Matsuzaki H, Aratani S, Ohshima T, Miyagishi M, et al. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci U S A. 2004; 101: 10042–10047. https://doi.org/10.1073/pnas.0400593101 PMID: 15220471
46. Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem. 2005; 280: 16456–16460. https://doi.org/10.1074/jbc.M501485200 PMID: 15716268
47. Doi T, Hamaguchi T, Shirao K, Chin K, Hatake K, Noguchi K, et al. Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Int J Clin Oncol. 2013; 18: 87–95. https://doi.org/10.1007/s10147-011-0348-6 PMID: 22234637
48. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007; 12: 1247–1252. https://doi.org/10.1634/theoncologist.12-10-1247 PMID: 17962618
49. Kubota N, Terauchi Y, Tobe K, Yano W, Suzuki R, Ueki K, et al. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest. 2004; 114: 917–927. https://doi.org/10.1172/JCI21484 PMID: 15467830